GANX News and Press, Gain Therapeutics Inc. From 05/17/21

BETHESDA, Md., May 17, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”), a biotechnology company focused on redefining drug discovery by identifying and optimizing allosteric binding sites that have never before been targeted, today announced that Eric ...

Gain Therapeutics (GANX): Q1 GAAP EPS of -$0.50 misses by $0.29.Revenue of $5.27M (-21.0% Y/Y)Press Release For further details see: Gain Therapeutics EPS misses by $0.29

Completed successful initial public offering and raised $46 million in gross proceeds --- Appointed four new independent board of directors to strengthen leadership team --- Signed a multi-target collaboration agreement with Zentalis Pharmaceuticals (Nasdaq: ZNTL) to d...

Compounds reverse the neurodegenerative process observed in a Parkinson’s disease in vivo model Compounds are novel allosteric regulators that bind, stabilize and restore activity of mutated GCase Compounds decrease both phosphorylated and aggregated α ...

BETHESDA, Md., April 27, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ: GANX) (“Gain”) a biotechnology company focused on redefining drug discovery by identifying and optimizing allosteric binding sites that have never before been targeted, today announced that Eric...

BETHESDA, Md., April 22, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ: GANX) (“Gain”), a biotechnology company focused on redefining drug discovery by identifying and optimizing allosteric binding sites that have never before been targeted, today announced a poster...

Gain Therapeutics ([[GANX]]) announces a multi-target collaboration agreement with Zentalis Pharmaceuticals ([[ZNTL]] -0.7%) to discover new product candidates for the treatment of cancer.Under the terms of the agreement, Gain will pursue binding site identification on target protei...

Collaboration to use Gain’s proprietary Site-Directed Enzyme Enhancement Therapy (SEE-Tx™) computational platform technology to identify new and previously difficult-to-drug oncology targets BETHESDA, Md., April 20, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc...

HOUSTON, April 14, 2021 (GLOBE NEWSWIRE) -- Coya Therapeutics, Inc., (Coya™), a clinical-stage biotechnology company developing first-in-class approaches utilizing autologous regulatory T cells (Tregs) and Treg-derived exosome therapeutics for neurodegenerative and autoimmune disease...

Piper Sandler paints an upbeat outlook for the synthetic biology (SynBio) space as the firm initiates coverage on Codexis (CDXS) and Twist Biosciences (TWST).Twist Bioscience and Codexis in focus as Piper Sandler sizes up synthetic biologyThe analyst Steven Mah predict the global market for s...